Go to the list of all blogs
John Y White's Avatar
published in Blogs
Oct 05, 2026
TickeronGET DAILY SIGNALS
ONMD vs ONMDW: Weighing OneMedNet's Common Stock Against Its Warrants

ONMD vs ONMDW: Weighing OneMedNet's Common Stock Against Its Warrants

Key Takeaways

  • Two different instruments, one company: ONMD is OneMedNet Corporation's common stock, while ONMDW is a derivative warrant tied to the same underlying business.
  • Distinct risk profiles: The common stock reflects the operating company directly, whereas the warrant adds leverage, time-decay, and exercise-price sensitivity on top of business fundamentals.
  • Strong bookings momentum: OneMedNet reported roughly $16.2 million in year-to-date bookings, a 16X increase versus the prior-year period, alongside a recent seven-figure multiyear agreement.
  • Recent corporate action: A 1-for-10 reverse stock split of ONMD took effect in late September 2026, resetting the common stock's share price and share count.
  • Liquidity contrast: ONMD trades with materially higher volume than ONMDW, which is a thinly traded, low-priced warrant with a wide range between its high and low.
  • Unprofitable fundamentals: Both instruments ultimately depend on a company that remains loss-making, so relative positioning hinges on growth catalysts versus near-term financial risk.

Two Securities Tied to the Same Business

Investors comparing ONMD and ONMDW are looking at two securities from the same issuer but with very different roles in a portfolio. ONMD represents the common stock of OneMedNet Corporation, a healthcare data and software provider, while ONMDW is a redeemable warrant that gives the holder the right to buy common stock at a set exercise price. This comparison matters for traders evaluating relative performance and for investors deciding between direct equity ownership and a more leveraged, derivative exposure to the same underlying company.

ONMD: The Common Stock View

OneMedNet Corporation (ONMD) operates the iRWD platform, which curates regulatory-grade, de-identified real-world data from medical imaging and clinical records for life sciences, medical device, and artificial intelligence customers. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Recent commercial traction includes a seven-figure multiyear agreement for multimodal clinical data with an AI-enabled precision medicine firm. A 1-for-10 reverse stock split took effect in late September 2026, which adjusted the share count and lifted the nominal price. ONMD has traded well below its 52-week high amid ongoing losses, even as bookings growth has outpaced recognized revenue.

ONMDW: The Warrant Perspective

ONMDW is the public warrant of OneMedNet Corporation, a derivative that allows the holder to purchase one share of common stock at a fixed exercise price. These warrants originated from the company’s 2023 SPAC business combination, after which the stock and warrants began trading separately on Nasdaq. The warrant does not confer direct ownership or voting rights until exercised. In recent trading, ONMDW has stayed at a low price level with thin daily volume, well below the exercise price, and the reverse split triggered standard anti-dilution adjustments to its terms.

Head-to-Head Comparison

The main difference between ONMD and ONMDW is structural. Both ultimately depend on OneMedNet’s ability to turn its growing bookings backlog into revenue and, eventually, profitability. The common stock provides a direct claim on the business with a simpler risk profile, while the warrant introduces embedded leverage, a specific exercise price, and greater sensitivity to time decay. ONMD has shown stronger trading activity and clearer price responses to announcements, whereas ONMDW’s limited liquidity produces sharper but less predictable moves. Both share the same growth drivers, such as rising demand for AI-related healthcare data, yet only the common stock delivers near one-for-one equity participation.

AI Framework Assessment

From what I see, observable factors such as trend consistency, liquidity, stability, and relative positioning suggest Tickeron’s AI framework would lean toward ONMD over ONMDW right now. The common stock delivers more consistent price behavior, higher trading volume, and a direct link to the company’s improving bookings trajectory. The warrant offers greater theoretical upside if the stock rises sharply, but its low liquidity and position well below the exercise price add extra uncertainty. A probabilistic view therefore favors the common stock as the more stable choice, though the warrant’s leverage could suit investors with a higher risk tolerance.

Using Tickeron’s Trending AI Robots for Strategy Ideas

In my own research process, I often review Tickeron’s Trending AI Robots to see which automated strategies are currently aligned with market conditions. The platform highlights a selection of AI-powered bots that trade thousands of tickers, each with its own style, timeframe, and performance history. This helps me cross-check ideas on names like ONMD without replacing my own analysis of fundamentals and liquidity.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ONMD

Contributor

John Y White's AvatarJohn Y White|Beginner

Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active&section=trades&via=john


ONMD in -9.16% downward trend, sliding for three consecutive days on November 16, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ONMD declined for three days, in 225 of 247 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ONMD as a result. In 45 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 57%.

The Moving Average Convergence Divergence Histogram (MACD) for ONMD turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 28 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 49%.

ONMD moved below its 50-day moving average on November 11, 2026 date and that indicates a change from an upward trend to a downward trend.

ONMD broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +43.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONMD advanced for three days, in 113 of 149 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

The Aroon Indicator entered an Uptrend today. In 55 of 233 cases where ONMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 24%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. ONMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ONMD's P/B Ratio (-86.621) is very low in comparison to the industry average of (4.523). P/E Ratio (-3.024) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. ONMD's P/S Ratio (23.529) is slightly higher than the industry average of (6.105).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 3.31B. The market cap for tickers in the group ranges from 708 to 49.18B. VEEV holds the highest valuation in this group at 49.18B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -13%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was 2%. DRIO experienced the highest price growth at 5%, while LFMD experienced the biggest fall at -34%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 27%. For the same stocks of the Industry, the average monthly volume growth was 34% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 53
Price Growth Rating: 58
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: -5 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ServicestotheHealthIndustry

Industry
N/A
Address
6385 Old Shady Oak Road
Phone
+1 800 918-7189
Employees
24
Web
https://www.onemednet.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.